International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 020-027
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Transarterial Chemo and Radioembolization (Yttrium90) of Hepatic Metastasis of Neuroendocrine Tumors: Single Center Experience
Fuat OZKAN1, Bora PEYNIRCIOGLU2, Barbaros E. CIL2, Nursel YURTTUTAN2, Suayib YALCIN3, Ferhun BALKANCI2
1Kahramanmaras Sutcu Imam University Faculty of Medicine, Department of Radiology, Kahramanmaras, TURKEY
2Hacettepe University Faculty of Medicine, Department of Radiology, Ankara, TURKEY
3Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
Keywords: Yttrium-90, Chemoembolization, Liver, Neuroendocrine tumors
The aim of this study was to present our single center experience with short (< 3 months) and intermediate-term (> 3 months) follow- up results of patients who underwent transarterial radioembolization with yttrium-90 microsphere (Y-90) or transarterial chemoembolization (TACE) for hepatic metastasis of neuroendocrine tumors (hmNETs). The results of 14 patients treated with either Y-90 or TACE were reviewed retrospectively. Clinical, laboratory, and imaging follow-up was performed. Efficacy was assessed by clinical and morphologic response. Survival was estimated by Kaplan-Meier analysis. Eight patients receiving 12 TACE treatments and 6 patients receiving 7 Y-90 treatments. Response rates were similar with two treatments at short-term follow-up, but there were a lower response rate and higher being progressive disease in the TACE group than Y-90 group at intermediate-term follow-up. However, progression-free survival was lower in Y-90 group (7.5 months) than TACE group (18 months). Regarding our limited experience, both Y-90 treatment and TACE have advantages and disadvantages in treatment of patients with hmNETs, however, randomized controlled studies, are needed.
Fuat OZKAN1, Bora PEYNIRCIOGLU2, Barbaros E. CIL2, Nursel YURTTUTAN2, Suayib YALCIN3, Ferhun BALKANCI2
1Kahramanmaras Sutcu Imam University Faculty of Medicine, Department of Radiology, Kahramanmaras, TURKEY
2Hacettepe University Faculty of Medicine, Department of Radiology, Ankara, TURKEY
3Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, TURKEY
Keywords: Yttrium-90, Chemoembolization, Liver, Neuroendocrine tumors
The aim of this study was to present our single center experience with short (< 3 months) and intermediate-term (> 3 months) follow- up results of patients who underwent transarterial radioembolization with yttrium-90 microsphere (Y-90) or transarterial chemoembolization (TACE) for hepatic metastasis of neuroendocrine tumors (hmNETs). The results of 14 patients treated with either Y-90 or TACE were reviewed retrospectively. Clinical, laboratory, and imaging follow-up was performed. Efficacy was assessed by clinical and morphologic response. Survival was estimated by Kaplan-Meier analysis. Eight patients receiving 12 TACE treatments and 6 patients receiving 7 Y-90 treatments. Response rates were similar with two treatments at short-term follow-up, but there were a lower response rate and higher being progressive disease in the TACE group than Y-90 group at intermediate-term follow-up. However, progression-free survival was lower in Y-90 group (7.5 months) than TACE group (18 months). Regarding our limited experience, both Y-90 treatment and TACE have advantages and disadvantages in treatment of patients with hmNETs, however, randomized controlled studies, are needed.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |